Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Structure for enhancing antibody drug stability

A technology for drugs and antibodies, applied in the field of genetic engineering, can solve the problems that antibody drugs are difficult to reach the target site, the drug efficacy is reduced, and the homodimer structure is easy to appear.

Active Publication Date: 2017-01-25
合肥诚志生物制药有限公司
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The structure of the drug has the following disadvantages: 1. The structure of some recombinant proteins is unstable. After forming a fusion protein with the antibody, there is only one peptide chain between the two, which may be broken. After the peptide chain is broken, the recombinant protein will lose its targeting. The efficacy is reduced, and even acting on non-lesional sites causes toxicity, and the half-life of recombinant protein drugs in vivo will also change
2. The free end of the recombinant protein drug is easily hydrolyzed and loses its biological activity. The half-life is short, which brings difficulties to industrialization
3. When antibody drugs adopt the single-chain antibody structure, homodimer structures are prone to appear, which brings difficulties to separation and purification, and the molecular weight of antibody drug dimers or multimers will have more space than antibody drug monomers Steric hindrance, which affects the tissue permeability of antibody drugs, making it difficult for antibody drugs to reach the target site

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Structure for enhancing antibody drug stability

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Example 1 Structural Design of Antibody Fusion Protein

[0021] The antibody fusion protein structure of the present invention is shown in figure 1 . VH and VL are the heavy chain variable region and light chain variable region of the antibody, respectively, and FP represents the recombinant protein. The three parts are connected by two peptide chains. Antibody fusion protein can be expressed by host cells through DNA recombinant technology.

Embodiment 2

[0022] Example 2 Antibody fusion protein drug

[0023] Fusion of the B5 antibody to human interleukin 2 (hIL2) to form the B5H-hIL2-B5L protein. The B5H-hIL2-B5L structure is that the heavy chain variable region of the protein B5 antibody is in the front, interleukin 2 is in the middle, and the light chain variable region of the B5 antibody is behind, and the three domains are connected by glycine-rich peptide chains . The amino acid sequence is shown in SEQ ID No.1.

[0024] The B5H-hIL2-B5L protein was obtained by secreting and expressing the protein from CHO (Chinese hamster ovary cells) cells and purifying it by cationic chromatography.

[0025] The purified B5H-hIL2-B5L protein was analyzed by SDS-PAGE denaturing electrophoresis and non-denaturing electrophoresis, and the molecular weight of the electrophoresis bands under both conditions was about 50kD. It suggested that B5H-hIL2-B5L was a monomer.

Embodiment 3

[0026] Example 3 Analysis of biological activity of antibody fusion protein

[0027] (1) IL2 biological activity of B5H-hIL2-B5L

[0028] B5H-IL2-B5L was added at 100 ng / ml to RPM1640 medium containing 10% fetal bovine serum to cultivate CTLL2 cells (mouse cytotoxic T lymphocytes), which can maintain the normal growth and continuous passage of CTLL2 cells. The hIL2 fused in the B5H-hIL2-B5L fusion protein has the biological activity of recombinant human IL2.

[0029] (2) Stability test of B5H-hIL2-B5L in plasma

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of a gene engineering drug. In the invention, an amino terminal and a carboxyl terminal of a recombinant protein are respectively connected to a heavy chain variable zone and a light chain variable zone of the antibody through a peptide bond, and a structure of antibody variable zone-recombination protein-antibody variable zone is formed, the recombination protein is connected with the antibody by two peptide bonds; thus the stability and targeting ability of the recombination protein are improved.

Description

technical field [0001] The invention belongs to the field of genetic engineering. Using DNA recombination technology to connect the light chain and heavy chain of the antibody into a recombinant protein to form a new antibody fusion protein, which can be used as a drug. Background technique [0002] Antibodies have good specificity and targeting, and the fusion or coupling of antibodies and drugs can make the drugs have corresponding specificity and targeting, so that the drugs can be enriched in the target tissue at a higher concentration. The antibody-recombinant protein drug fusion protein composed of antibody and recombinant protein drug molecule is one of the directions of drug design and development, but the structure of this type of drug is characterized by the fusion of recombinant protein drug upstream or downstream of the single-chain antibody (Muller (2014). BioDrugs. 28: 123-131.), the remarkable feature of the antibody drug structure is that there is only one p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00A61K38/02
CPCA61K38/00C07K14/00C07K16/00C07K2319/01
Inventor 张美季俊虬高美华陈军
Owner 合肥诚志生物制药有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com